Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse-Reference-Cited by-同舟云学术

Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

Published:2015-10-01 Issue:14 Volume:126 Page:1695-1698
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bernard Sophie¹²,Goldwirt Lauriane³,Amorim Sandy¹²,Brice Pauline¹,Brière Josette⁴,de Kerviler Eric⁵,Mourah Samia²⁶⁷,Sauvageon Hélène³,Thieblemont Catherine¹²

Affiliation:

1. Hemato-oncology Department, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Paris, France;

2. Paris Diderot Université, Sorbonne Paris Cité, Paris, France;

3. Pharmacology Department, APHP, Hôpital Saint-Louis, Paris, France;

4. Pathology Department, APHP, Hôpital Saint-Louis, Paris, France;

5. Radiology Department, APHP, Hôpital Saint-Louis, Paris, France;

6. INSERM UMR-S 976, Hôpital Saint-Louis, Paris, France; and

7. Pharmacology-Genetics Laboratory, APHP, Hôpital Saint-Louis, Paris, France

Abstract

Key Points Ibrutinib induces a rapid, dramatic, and sustained response in MCL patient with symptomatic CNS relapse. Ibrutinib penetration through the blood-brain barrier was confirmed using plasma and cerebrospinal fluid pharmacokinetic analyses.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/14/1695/1388821/1695.pdf

Reference17 articles.

1. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.;Cheah;Ann Oncol,2013

2. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.;Honigberg;Proc Natl Acad Sci USA,2010

3. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

4. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.;Wang;Blood,2015

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update;Annals of Hematology;2024-07-25

2. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma;Clinical Cancer Research;2024-07-12

3. Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances;Leukemia & Lymphoma;2024-04-10

4. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma;European Journal of Cancer;2024-01

5. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024